Mechanical |
Biological |
Durable—valves lasting 20-30 years |
Limited life span—10% of homografts and 30% of heterografts fail within10-15 years |
Thrombogenic—patients require lifelong anticoagulant therapy |
Low thrombogenic potential—lifelong anticoagulation is not required |
Preferred in younger patients with >10-15 years life expectancy |
Preferred in older patients with <10-15 years life expectancy |
Preferred in patients who require lifelong anticoagulant therapy |
Preferred in those who cannot (or will not) take lifelong anticoagulant therapy |